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ABSTRACT
Herein a series of novel thiosemicarbazones (TSCs) derived from 2-oxoquinoline scaffold is reported, and the target compounds
have been successfully synthesized and characterized using standard spectroscopic techniques. The in vitro biological activities
of synthesized molecules were evaluated against Plasmodium falciparum malaria parasites (strain 3D7), Trypanosoma brucei
brucei parasites (strain 427) and HeLa cells. All the compounds displayed modest or no activity at a concentration of 20 µM and
percentage viability of >50 % was often observed. Except for compound 9o, none of the final compounds exhibited cytotoxic
effects against HeLa cells at 20 µM.
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1. Introduction
Malaria, an infectious parasitic disease, is a major health risk in
many developing countries worldwide.1 Despite tremendous
progress over the last two decades, in 2017 there were 216 mil-
lion cases of malaria infection, with an estimated 445 000 deaths,
90 % of which occur in sub-Saharan Africa.1,2 Currently, it is
estimated that almost 3.2 billion people globally are at risk of
contracting the disease.3 This is further aggravated by the wide-
spread drug and multidrug resistant Plasmodium falciparum
parasite, the main cause of infection in humans, to almost all
antimalarial drugs that are in clinical use.4 In the absence of an
effective malaria vaccine, the need to discover and develop new
antimalarial drugs, with unique structural motifs and new mode
of action, that are safe and effective against highly resistant para-
sites is imperative.4,5
On other hand, human African trypanosomiasis (HAT),
commonly referred to as a sleeping sickness, is caused by proto-
zoan parasites of the genus Trypanosoma, and the two species
that are transmitted to humans by blood-feeding tsetse flies
(Glossina spp.) are Trypanosoma brucei gambiense and Trypanosoma
brucei rhodesiense.6,7 Up to 70 million people, in various parts of
the 36 countries in Africa where the disease is endemic, are at risk
of infection.6 While the cases of HAT in Africa have been reason-
ably low, in 2015 an estimated 3000 new infections of East and
West African trypanosomiasis were reported to the World
Health Organisation (WHO).8 Regrettably, in pregnant women
or those of child-bearing age, the disease causes infertility and
abortion, and it is invariably fatal if left untreated.8 Currently,
only a handful of drugs are available for the treatment of HAT,
and are utilized based on the causative trypanosome species and
stage of the disease.8 For example, pentamidine and suramin are
recommended for treatment of the acute initial stage of T. b.
gambiense, while a combination of nifurtimox-eflornithine and
melarsoprol are deployed for the secondary stage of the disease.
For T. b. rhodesiense, suramin is a preferred drug for treatment of
the initial stage of the disease, while melarsoprol is reserved for
secondary stage chemotherapy.9 However; these drugs have
shortcomings and some of them are associated with life-
threatening side effects that have prompted the scientific
community to search for new compounds with desirable safety
margins and drug-like properties to replace them.
Thiosemicarbazones are a class of compounds which have
enjoyed significant attention due to their broad-spectrum of
biological activities, including antibacterial, antiprotozoal,
antifungal, antiviral and antitumour activity.10 Quinoline and
related derivatives, on the other hand, are useful compounds
with diverse pharmaceutical applications, and some have even
reached markets for treatment of various ailments.11 The 2-oxo-
quinoline (2-OCQ), which belongs to a quinoline family, is an
interesting naturally occurring scaffold to attach new moieties
or bioactive groups and it has been widely used as a ‘parental’
framework to synthesize a variety of molecules with a wide
range of biological activities such as antitubercular, anti-
inflammatory, antifungal and antileishmanial activity.12–15 For
example, oxoquinoline-derived thiosemicarbazones I and III
(Fig. 1) were found to exhibit good antiproliferative activity
against the HCT116 cell line.16
In our pursuit of developing biologically relevant molecules,
that could address some of the problems associated with
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infections caused by protozoan parasites, we are interested in
exploring a class of 2-oxoquinoline-derived thiosemicarbazone
derivatives as antiplasmodial and antitrypanosomal agents. To
the best of our knowledge, there has been no report on the anti-
plasmodial and antitrypanosomal properties of these com-
pounds in literature. To this end, in this study we report on the
synthesis of quinoline-derived thiosemicarbazones and their
in vitro bioassay screening against P. falciparum 3D7 strain and
T. b. brucei (strain 427) as well as cytotoxicity evaluation against
HeLa cell lines.
2. Results and Discussion
2.1. Synthesis
The synthesis of target quinoline-derived thiosemicarbazone
derivatives is outlined in Scheme 1. Commercially available
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Figure 1 Chemical structures of biologically active quinoline-derived thiosemicarbazone derivatives (I and II) based on 2-oxo-quinoline structural
motif.
Scheme 1
(i) Acetic acid, acetic anhydride (1:1), reflux, 0.5 h; (ii) DMF, POCl3, 85 °C, 12 h; (iii) acetic acid, 90 °C, 8 h; (iv) propargyl bromide, DMF, K2CO3,
25 –60 °C, 4 h; (v) azide, CuI, 2,6-lutidine, 0 °C, 12 h; (vi) benzylbromides (R3-X), DMF, K2CO3, r.t – 60 °C, 1–12 h; (vii) aminoquinolines, DMF, 0 °C,
NaH, 1 h, 60 °C, 12 h; (viii) thiosemicarbazide, MeOH or EtOH, 80 °C, 10 –15 h.
anilines 1a–c were treated with a solution of acetic acid and
acetic anhydride (1:1 mole ratio) under reflux to generate the
corresponding acetanilides 2a–c in moderate yields.17 The
Vilsmeier-Haack reaction18 involving the condensation of resul-
tant acetanilides 2a–c with N,N-dimethylformamide (DMF), in
the presence of phosphorusoxychloride (POCl3), was then used
to produce 2-chloroquinoline-3-carbaldehyde derivatives 3a–c.18
The next step involved accessing the desired key intermedi-
ates, 2-oxoquinoline-3-carbaldehyde derivatives 4a–d, via a
previously reported literature methods.19 Thus, the hydrolytic
reaction of 3a–c in 70 % acetic acid aqueous solution resulted
in quinolinone derivatives 4a–c, which were obtained in yields
ranging from 38–62 %. To access compounds 4d, commercial
available 2-chloroquinoline-3-carbaldehyde was reacted, under
similar reaction conditions as in the synthesis of 4a–c, to yield the
desired compound 4d in 69 % yield. With the desired key inter-
mediates (4a–c) in hand, propargylation reaction using
propargyl bromide yielded propargyl quinoline aldehydes 5a–c,
which were then further reacted with appropriate azides, under
the copper-catalyzed azide-alkyne cycloaddition (CuAAC) con-
ditions,20–23 to form 1,4-disubstituted-1,2,3-triazoles quinoline
aldehydes 6a–c in yields ranging from 42–61 %.
Similarly, reacting the key intermediates 4a–c with substituted
benzylbromides and 7-chloro-N-(2-chloropropyl)quinolin-
4-amine yielded quinoline aldehydes 7a–f and 8b in moderate
yields, respectively. Compound 8a could not be isolated in its
pure form, and instead it was reacted with thiosemicarbazide
(step viii) as crude product to form the desired quinoline-
derived thiosemicarbazone 9n. Lastly, all the quinoline alde-
hydes 5a–c, 6a–c, 7a–f and 8b were then subjected to the Schiff
base condensation reaction with commercially accessible
thiosemicarbazide in refluxing MeOH or EtOH to give rise to
the desired 2-oxoquinoline-based thiosemicarbazone deriva-
tives 9a–r (Table 1) in moderate to excellent yields.24–26 All the
intermediates and target compounds were fully characterized
by analytical and spectroscopic techniques.
2.2. In Vitro Biological Evaluation
The prepared target compounds were evaluated in vitro for
antiplasmodial activity against the chloroquine sensitive (CQS)
3D7 P. falciparum, the trypanosomal subspecies responsible for
nagana T. b. brucei, and for cytotoxicity evaluation using a human
cervix adenocarcinoma (HeLa) cell line. Chloroquine (CQ) was
included as a positive control for P. falciparum and pentamidine
(PMD) was employed for T. b. brucei assays while emetine (EMT)
was a positive control drug for HeLa cells. The screening assay
was done using the malaria parasite lactate dehydrogenase
Pf(pLDH), T. b. brucei and HeLa cell resazurin assays that were
performed in duplicates using 20 mM final concentrations of
each compound. The percentage cell viability results upon expo-
sure of P. falciparum, T. b. brucei and HeLa cells to the compounds
are displayed in Table 2.
The tested compounds (Table 2) exhibited no cytotoxic effects
(percentage viability >64 %) as measured by the viability of
HeLa cell lines at a concentration of 20 µM, the exception is com-
pound 9o which reduced HeLa cell viability to 6.6 %. Excluding
compounds 9m, 9n and 9o, which reduced the percentage para-
site viability to below 20 %, none of the tested target compounds
displayed desirable potency at the concentration of 20 µM.
These compounds were evaluated further to determine the
corresponding IC50 values (Fig. 2) against the 3D7 strain of the
parasite P. falciparum. And while 9m emerged as inactive, com-
pounds 9n and 9o displayed notable activity with the corre-
sponding IC50 values of 2.09 and 1.79 µM, respectively. These
data suggest that the observed antiplasmodial activity may
be related to the presence of aminoquinoline moiety in each
molecule, which is known to bind with haem, thus preventing
the formation of haemozoin. However, the corresponding
quinoline aldehyde intermediates 6c and 8b were ineffective
(data not included) at the maximum tested concentration
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Table 1 Synthesized quinoline-based thiosemicarbazones 9a–r and their
isolated yields.
Comp R R1 R2 Yield/%
9a H H H 70
9b H CH3 H 68
9c CH3 H H 60
9d OCH3 H H 63
9e H H 42
9f H H 54
9g OCH3 H 38
9h OCH3 H 44
9i CH3 H 41
9j CH3 H 57
9k H H 69
9l CH3 H 56
9m OCH3 H 69
9n H H 56
9o H H 48
9p H H 45
9q H H 55
9r H H 42
(20 mM) suggesting that enhanced activity of 9n and 9o could be
attributed to the contribution of the thiosemicarbazone and
4-aminoquinoline fragments.27
Similarly, in terms of antitrypanosomal activity, none of the
tested compounds exhibited appreciable activity except com-
pounds 9n and 9o, which reduced the viability of trypanosomes
(T. b. brucei) at 20 µM to 12.7 % and 12.8 %, respectively. Since
compound 9o showed a significant cytotoxic effect at 20 µM,
only compound 9n was further screened to determine the
corresponding IC50 value (Fig. 3). Despite significant growth
inhibition as measured by the viability of trypanosomes,
compound 9n was found to be inactive with IC50 value of
167.7 µM.
3. Conclusion
In summary, a series of thiosemicarbazone derivatives 9a–r
based on the 2-oxoquinoline structural motif have been
prepared in moderate to excellent yields and their structural
integrity confirmed using various spectroscopic techniques.
Despite the poor antiplasmodial and antitrypanosomal activity
of the majority of the tested compounds, the promising potency
of 9n and 9o provides an avenue for further in-depth investiga-
tion of these bi-quinoline thiosemicarbazone compounds as a
new family of quinoline-based anti-infective agents. Apart from
compounds 9m, 9n and 9o, which exhibited weak to good
activity with IC50 (T. b. brucei) = 167.7 µM and IC50s (Pf) = 2.09
and 1.79 µM values, the rest of compounds were inactive and
parasite percentage viabilities of >50 % were often observed.
As determined by the HeLa cell line, the majority of these
compounds showed no significant toxicity.
4. Experimental
4.1. General
All commercially available chemicals and reagents were pur-
chased from Sigma-Aldrich (Pty) Ltd and Merck (Pty) Ltd, and
were used without further purification unless stated otherwise.
The progress of reactions were monitored by analytical thin
layer chromatography (TLC) using Merck F254 silica gel plates
(supported on aluminium), which were visualized under ultra-
violet (UV 254 and 366 nm) light or, where necessary, stained in
iodine flask. The crude compounds were purified by flash col-
umn chromatography using Merck Kieselgel 60 Å: 70–230 silica
gel mesh or by preparative thin-layer chromatography (PTLC)
using Merck 60GF254 silica gel coated on glass plates (2.0 × 200 ×
200 mm). The 1H and 13CNMR spectra were recorded on either a
Bruker Fourier 300 or a 400 MHz spectrometer. Spectra were
recorded in deuterated solvents: CDCl3-d6 and DMSO-d6. All
chemical shift values are reported in parts per million (ppm)
referenced to residual solvent resonances (CDCl3 dH 7.26, dC 77.2;
DMSO dH 2.50, dC 39.5). The coupling constants are given in
Hertz. High resolution mass spectrometry was performed on a
Waters Synapt G2 TOF instrument with an ESI source, Univer-
sity of Stellenbosch. Measurement of the melting points was
carried out using a Reichert hot stage microscope (Protea Hold-
ings Ltd.) and uncorrected. Elemental microanalysis was per-
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Table 2: In vitro antiplasmodial and antitrypanosomal activity, and
cytotoxicity evaluation of target compounds 9a–r. The IC50 values (in µM)
obtained with the standard drug compounds CQ, PMD and EMT are
also shown.
%Viability at 20 µM
Comp 3D7 T. brucei Cytotoxicity
9a 79.1 114.5 84.8
9b 66.1 103.1 64.8
9c 78.5 115.1 110.2
9d 81.6 112.3 95.1
9e 97.1 116.1 89.9
9f 49.3 104.3 85.1
9g 97.1 52.8 102.3
9h 81.6 118.4 83.3
9i 72.2 108.6 96.0
9j 101.4 102.3 94.1
9k 103.9 92.7 62.0
9l 85.9 111.7 111.2
9m 17.6 90.3 100.2
9n –2.5 12.7 90.8
9o –4.4 12.8 6.6
9p 87.0 115.3 112.4
9q 74.5 98.8 106.8
9r 31.3 112.8 105.5
CQ 0.028 – –
PMD – 0.0028 –
EMT – – 0.37
Figure 2 Plot of percentage antiplasmodial activity against log concentration for compounds 9m, 9n, 9o and the standard drug, chloroquine.
formed on Elementar Analysensysteme varioMICRO V1.6.2
GmbH analysis system.
4.2. General Procedure for Synthesis of Thiosemicarbazone
Compounds 9a–r
An appropriate starting 2-oxoquinoline-3-carbaldehyde (0.081
g, 0.5 ), and thiosemicarbazide (0.5 mmol) were mixed in metha-
nol (25 mL) and heated to 80 °C for 10 h. After reaction comple-
tion, the resulting product was allowed to cool to ambient
temperature and resulted in the formation of a precipitate,
which was filtered, washed with ice-cold MeOH and dried to
give the desired products.
(E)-2-((2-oxo-1,2-dihydroquinolin-3-yl)methylene)hydrazinecarbo-
thioamide (9a): 70 % yield; yellow solid; mp 290–293 °C (Lit28
296 °C); dH(300 MHz; DMSO-d6): 12.1 (1H, s, N(1)H), 11.7 (1H, s,
N(11)H), 8.83 (1H, s, H4), 8.76 (1H, s, H9), 8.32 (1H, br s, NHH), 8.27
(1H, s, H4), 8.11 (1H, br s, NHH), 7.64 (1H, dd, J = 1.1 and 8.0 Hz,
H5), 7.52 (1H, ddd, J = 1.4, 7.3 and 9.2 Hz, H6), 7.30 (1H, dd, J = 0.8
and 8.0 Hz, H8), 7.22 (1H, ddd, J = 0.9, 7.3 and 9.1 Hz, H7) ppm;
dC (75 MHz, DMSO-d6): 178.1, 161.0, 139.0, 136.8, 135.2, 131.1,
128.6, 125.4, 122.5, 119.3, 115.3 ppm; vmax(neat, cm
–1): 3291 (NH),
3173 (NH), 1638 (C=O), 1533 (C=S), 851 (C-S); HRMS (ESI)
m/z calcd for C11H10N4OS 246.0575, found 247.0662 [M+H]
+;
Anal. calcd for C11H10N4OS·0.125H2O: C, 53.16; H, 4.16; N, 22.54;
S, 12.90 %. Found: C, 53.18; H, 3.95; N, 22.54; S, 12.96 %.
(E)-2-((8-Methyl-2-oxo-1,2-dihydroquinolin-3-yl)methylene)hydra-
zinecarbothioamide (9b): 63 % yield; yellow solid; mp 246–248 °C;
dH(300 MHz; DMSO-d6): 11.6 (1H, s, N(1)H), 11.2 (1H, s, N(11)H),
8.76 (1H, s, H9), 8.29 (2H, s, NHH), 8.28 (1H, s, H4), 8.01 (1H, br s,
NHH), 7.50 (1H, d, J = 7.8 Hz, H5), 7.37 (1H, d, J = 7.5 Hz, H7), 7.14
(1H, t, J = 8.0 Hz, H6), 2.43 (3H, s, CH3) ppm; dC(75 MHz,
DMSO-d6): dC 178.1, 161.5, 137.3, 136.7, 135.8, 132.3, 126.7, 125.0,
123.6, 122.2, 119.3, 17.2 ppm; vmax(neat, cm
–1): 3269 (NH), 3154
(NH), 1645 (C=O), 1531 (C=S), 856 (C-S); HRMS (ESI) m/z calcd
for C12H12N4OS: 260.0732, found 261.0808 [M+H]
+; Anal. calcd
for C12H12N4OS·0.75H2O: C, 52.64; H, 4.97; N, 20.46; S, 11.71 %.
Found: C, 52.61; H, 4.97; N, 20.48; S, 11.57 %.
(E)-2-((6-Methyl-2-oxo-1,2-dihydroquinolin-3-yl)methylene)hydra-
zinecarbothioamide, (9c): 60 % yield; orange solid; mp 248–250 °C;
dH(300 MHz; DMSO-d6): 11.9 (1H, s, N(1)H), 11.6 (1H, s, N(11)H),
8.68 (1H, s, H9), 8.29 (1H, br s, NHH), 8.27 (1H, s, H4), 8.07 (1H, s,
NHH), 7.27 (3H, m, H5, H7 and H8) 2.33 (3H, s, CH3) ppm;
dC(75 MHz, DMSO-d6): d 178.1, 160.9, 137.0, 136.9, 134.7, 132.3,
131.3, 127.9, 125.2, 119.2, 115.1, 20.4 ppm; vmax(neat, cm
–1): 3256
(NH), 3148 (NH), 1525 (C=N), 1646 (C=N), 1208 (C=S), 863
(C-S); HRMS (ESI) m/z calcd for C12H12N4OS [M+H]
+ 260.0732,
found 261.0823; Anal. calcd for C12H12N4OS·0.75H2O: C, 52.64;
H, 4.97; N, 20.46; S,11.71 %. Found: C, 52.51; H, 5.08; N, 20.13;
S, 11.50 %.
(E)-2-((6-Methoxy-2-oxo-1,2-dihydroquinolin-3-yl)methylene)hydra-
zinecarbothioamide (9d): 69 % yield; orange solid; mp 255–256 °C
(Lit.29 258–260 °C); dH(300 MHz; DMSO-d6): 11.8 (1H, s, N(1)H),
11.6 (1H, s, N(11)H), 8.72 (1H, s, H9), 8.31 (1H, br s, NHH), 8.27
(1H, s, H4), 8.05 (1H, br s, NHH), 7.26 (1H, d, J = 8.9 Hz H8), 7.18
(1H, dd, J = 2.8 and 8.9 Hz, H7), 7.12 (1H, d, J = 2.8 Hz, H5), 3.71
(3H, s, CH3) ppm; dC(75 MHz, DMSO-d6): 178.1, 160.5, 154.4,
136.8, 134.7, 133.6, 125.6, 120.5, 119.7, 116.5, 109.2, 55.4 ppm;
vmax(neat, cm
–1): 3392 (NH), 3160 (NH), 1647 (C=O), 1530 (C=S),
840 (C-S); HRMS (ESI) m/z calcd for C12H12N4O2S: 276.0681,
found 277.0747 [M+H]+. Anal. Calcd for C12H12N4O2S: C, 52.16;
H, 4.38; N, 20.28; S, 11.60. Found (%): C, 52.11; H, 4.28; N, 20.23;
S, 11.57 %.
(E)-2-((1-Benzyl-2-oxo-1,2-dihydroquinolin-3-yl)methylene)hydra-
zinecarbothioamide (9e): 42 % yield; yellow solid; mp 222–224 °C;
dH(400 MHz; DMSO-d6): 11.7 (1H, s, N(11)H), 8.86 (1H, s, H9),
8.39 (1H, s, H4), 8.34 (1H, br s, NHH), 8.14 (1H, br s, NHH), 7.73
(1H, dd, J = 1.2 and 7.8 Hz, H5), 7.53 (1H, ddd, J = 1.4, 7.5 and 8.6
Hz, H6), 7.43 –7.18 (7H, m, Ar-Hs), 5.57 (2H, s, H1a) ppm;
dC(101 MHz, DMSO-d6): 178.1, 160.6, 138.9, 137.0, 135.7, 134.7,
131.3, 129.6, 128.6, 127.1, 126.5, 124.5, 122.7, 120.2, 115.2, 45.0 ppm;
vmax(neat, cm
–1): 3201 (NH), 3147 (NH), 1626 (C=O), 1517 (C=N),
1207 (C=S), 855 (C-S); HRMS (ESI) m/z calcd for C18H16N4OS
336.1045, found 337.1136 [M+H]+; Anal. calcd for C18H16N4OS:
C, 64.26; H, 4.79; N, 16.65; S, 9.53. Found: C, 65.16; H, 5.86;
N, 14.99; S, 8.63 %.
(E)-2-((1-(4-Nitrobenzyl)-2-oxo-1,2-dihydroquinolin-3-ylyl)methy-
lene)hydrazinecarbothioamide (9f): 52 % yield; yellow solid; mp
235–237 °C; dH(400 MHz; DMSO-d6): 11.7 (1H, s, N(11)H), 8.89
(1H, s, H9), 8.38 (1H, s, H4), 8.36 (1H, br s, NHH), 8.20–8.16 (2H, m,
H3’ and H5’), 8.15 (1H, br s, NHH), 7.76 (1H, d, J = 7.6 Hz, H8), 7.54
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Figure 3 Plot of percentage antitrypanosomal activity against log concentration for compound 9n and the standard drug, pentamidine.
(1H, t, J = 8.7 Hz, H6), 7.37 (1H, d, J = 8.7 Hz, H5), 7.31 (2H, t, 7.4
Hz, H7), 5.70 (2H, s, H1a) ppm; dC(101 MHz, DMSO-d6): 178.1,
160.6, 146.6, 144.6, 138.7, 136.8, 135.0, 131.5, 129.8, 127.8, 124.6,
123.8, 123.0, 120.3, 115.3, 44.9 ppm; vmax(neat, cm
–1): 3216 (NH),
3148 (NH), 1633 (C=O), 1516 (C=N), 1203 (C=S), 850 (C-S);
HRMS (ESI) m/z calcd for C18H13N5O3S 381.0896, found 382.0968
[M+H]+; Anal. calcd for C18H13N5O3S·0.5CH3OH: C, 56.19;
H, 3.82; N, 17.71; S, 8.11 %. Found: C, 56.61; H, 3.91; N, 17.38;
S, 8.34 %.
(E)-2-((1-Benzyl-6-methoxy-2-oxo-1,2-dihydroquinolin-3-yl)methy-
lene)hydrazinecarbothioamide (9g): 41 % yield; yellow solid; mp
232–234 °C, dH(400 MHz; DMSO-d6): d 11.7 (1H, s, N(11)H), 8.81
(1H, s, H9), 8.38 (1H, s, H4), 8.36 (1H, br s, NHH), 8.09 (1H, br s,
NHH), 7.36–7.27 (3H, m, H5, H7 and H8), 7.25–7.15 (5H, m,
H2’,H3’,H4’,H5’ and H6’), 5.57 (2H, s, H1a), 3.79 (3H, s, CH3) ppm;
dC(101 MHz, DMSO-d6): 178.1, 160.1, 154.4, 137.1, 136.6, 134.3,
133.5, 128.6, 127.0, 126.5, 124.9, 120.9, 120.0, 116.6, 110.8, 55.4,
45.0 ppm; vmax(neat, cm
–1): 3275 (NH), 3157 (NH), 1635 (C=O),
1518 (C=N), 1202 (C=S), 869 (C-S); HRMS (ESI) m/z calcd for
C19H18N4O2S: 366.1150, found 367.1213 [M+H]
+; Anal. calcd for
C19H18N4O2S·0.25H2O; C, 61.52; H, 5.03; N, 15.10; S, 8.64 %.
Found: C, 61.37; H, 4.92; N, 15.03; S, 8.72 %.
(E)-2-((6-Methoxy-1-(4-nitrobenzyl)-2-oxo-1,2-dihydroquinolin-3-yl
)methylene)hydrazinecarbothioamide (9h): 57 % yield; yellow solid;
mp 238–240 °C; dH(400 MHz; DMSO-d6): 11.7 (1H, s, N(11)H),
8.85 (1H, s, H4), 8.37 (1H, br s, NHH), 8.17 (2H, d, J = 8.8 Hz,
H3’and H5’), 8.10 (1H, br s, NHH), 7.45 (2H, d, J = 8.8 Hz, H2’ and
H6’), 7.31 (1H, d, J = 9.3 Hz, H8), 7.24 (1H, d, J = 2.9 Hz, H5), 7.17
(1H, dd, J = 2.9 and 9.2 Hz, H7), 5.68 (2H, s, H1a), 3.80 (3H, s,
CH3) ppm; dC(101 MHz, DMSO-d6): 178.1, 160.1, 154.6, 146.6,
144.7, 136.9, 134.5, 133.3, 127.7, 124.9, 123.8, 121.0, 120.1, 116.4,
111.8, 55.4, 44.8 ppm; vmax(neat, cm
–1): 3215 (NH), 3155 (NH), 1636
(C=O), 1511 (C=N), 1206 (C=S), 860 (C-S); HRMS (ESI) m/z calcd
for C19H17N5O4S: 411.1001, found 412.0810 [M+H]
+; Anal. calcd
for C19H17N5O4S: C, 55.47; H, 4.16; N, 17.02; S, 7.79 %. Found:
C, 55.32; H, 4.28; N, 17.08; S, 7.97 %.
(E)-2-((1-Benzyl-6-methyl-2-oxo-1,2-dihydroquinolin-3-yl)methy-
lene)hydrazinecarbothioamide (9i): 38 % yield; yellow solid; mp
236–238 °C; dH(400 MHz; DMSO-d6): 11.7 (1H, s, N(11)H), 8.79
(1H, s, H9), 8.38 (1H, s, H4), 8.33 (1H, br s, NHH), 8.14 (1H, br s,
NHH), 7.51 (1H, d, J = 1.5 Hz, H5), 7.35 (1H, dd, J = 1.6 and 8.6 Hz,
H7), 7.32–7.27 (3H, m, H8, H2’ and H6’), 7.25–7.17 (3H, m, H3’, H4’
and H5’), 5.54 (2H, s, H1a), 2.34 (1H, s, CH3) ppm; dC(101 MHz,
DMSO-d6): 178.1, 160.5, 137.1, 137.0, 136.6, 134.5, 132.5, 131.7,
129.1, 128.6, 127.0, 126.5, 124.5, 120.1, 115.2, 44.9, 20.0 ppm;
vmax(neat, cm
–1): 3191 (NH), 3151 (NH), 1633 (C=O), 1522 (C=N),
1203 (C=S), 835 (C-S); HRMS (ESI) m/z (calcd for C19H18N4OS:
350.1201, found 351.1273 [M+H] + ; Anal . calcd for
C19H18N4OS·0.25H2O: C, 64.29; H, 5.25; N, 15.78; S, 9.03 %. Found:
C, 64.10; H, 5.24; N, 15.78; S, 9.22 %.
(E)-2-((6-Methyl-1-(4-nitrobenzyl)-2-oxo-1,2-dihydroquinolin-3-yl)
methylene)hydrazinecarbothioamide (9j): 44 % yield; yellow solid;
mp 241–243 °C; dH(400 MHz; DMSO-d6): 11.7 (1H, s, N(11)H),
8.83 (1H, s, H9), 8.37 (1H, s, H4), 8.35 (1H, br s, NHH), 8.17–8.16
(2H, m, H3’ and H5’), 8.12 (1H, br s, NHH), 7.52 (1H, d, J = 1.3 Hz,
H5), 7.47–7.43 (2H, m, H2’ and H6’), 7.37 (1H, dd, J = 1.7 and 8.7 Hz,
H7), 7.27 (1H, d, J = 8.7 Hz, H8) ppm; dC(101 MHz, DMSO-d6):
178.1, 160.5, 146.6, 144.7, 136.9, 136.8, 134.8, 132.7, 132.0, 129.3,
127.7, 124.5, 123.8, 120.2, 114.9, 44.7, 20.0 ppm; vmax(neat, cm
–1):
3215 (NH), 3150 (NH), 1638 (C=O), 1520 (C=N), 1205 (C=S), 850
(C-S); HRMS (ESI) m/z calcd for C19H17N5O3S: 395.1052, found
396.1135 [M+H]+; Anal. calcd for C19H17N5O3S·0.25H2O: C, 57.06;
H, 4.41; N, 17.51; S, 8.02 %. Found: C, 56.78; H, 3.98; N, 17.11;
S, 7.98 %.
(E)-2-((2-Oxo-1-(prop-2-yn-1-yl)-1,2-dihydroquinolin-3-yl)methy-
lene)hydrazinecarbothioamide (9k): 59 % yield; yellow solid; mp
258 °C (Decomposed); dH(400 MHz; DMSO-d6): 11.7 (1H, s,
N(11)H), 8.83 (1H, s, H9), 8.36 (1H, br s, NHH), 8.32 (1H, s, H4), 8.14
(1H, br s, NHH), 7.72 (1H, m, H7 and H8), 7.61 (1H, d, J = 8.5 Hz,
H5), 7.36 (1H, t, J = 7.95 Hz, H6), 5.13 (2H, d, J = 1.9 Hz, H1a), 3.29
(1H, t, J = 2.2 Hz, H2¢); dC(101 MHz, DMSO-d6): 178.1, 159.6,
138.2, 136.7, 136.6, 131.4, 129.6, 124.4, 123.0, 120.1, 115.1, 78.6, 74.6,
31.4 ppm; vmax(neat, cm
–1): 3272 (NH), 3156 (NH), 1645 (C=O),
1532 (C=S), 846 (C-S); HRMS m/z calcd for C14H12N4OS 284.0732,
found: 285.0819 [M+H]+; Anal. calcd for C14H12N4OS·0.125H2O:
C, 58.67; H, 4.31; N, 19.55; S, 11.19 %. Found: C, 58.69; H, 3.81;
N, 19.38; S, 11.15 %.
(E)-2-((6-methoxy-2-oxo-1-(prop-2-ynyl)-1,2-dihydroquinolin-3-yl)
methylene)hydrazinecarbothioamide (9l): 56 % yield; yellow solid;
mp 232 °C (Decomposed); dH(400 MHz; DMSO-d6): 11.6 (1H, s,
N(11)H), 8.70 (1H, s, H9), 8.30 (1H, br s, NHH), 8.32 (1H, s, H4), 8.09
(1H, br s, NHH), 7.46 (1H, d, J = 9.3 Hz, H8), 7.25 (1H, dd, J = 2.9
and 9.2 Hz, H7), 7.15 (1H, d, J = 2.9 Hz, H5), 5.03 (2H, d, J = 2.1 Hz,
H1a), 3.75 (3H, s, CH3), 3.18 (1H, t, J = 2.2 Hz, H2¢) ppm;
dC(101 MHz, DMSO-d6): 178.1, 159.1, 154.6, 136.7, 134.3, 132.8,
124.8, 120.8, 120.1, 116.5, 110.9, 78.8, 74.5, 55.4, 31.4 ppm;
vmax(neat, cm
–1): 3258 (NH), 3172 (NH), 1635 (C=O), 1203 (C=S),
1521 (C=N), 849 (C-S); HRMS (ESI) m/z calcd for C15H14N4O2S:
298.0888, found 299.0805 [M+H]+; Anal. calcd for C15H14N4O2S:
C, 56.94; H, 5.10; N, 17.71; S, 10.14 %. Found: C, 56.52; H, 5.19;
N, 17.58; S, 10.33 %.
(E)-2-((6-Methyl-2-oxo-1-(prop-2-yn-1-yl)-1,2-dihydroquinolin-3-yl)
methylene)hydrazinecarbothioamide (9m): 60 % yield; yellow solid;
mp 244 °C (Decomposed); dH (400 MHz; DMSO-d6): 11.6 (1H, s,
N(11)H), 8.75 (1H, s, H9), 8.35 (1H, br s, NHH), 8.32 (1H, s, H4), 8.07
(1H, br s, NHH), 7.55 (1H, d, J = 9.3 Hz, H8), 734 (1H, dd, J = 2.9
and 9.2 Hz, H7), 7.23 (1H, d, J = 2.9 Hz, H5), 5.11 (1H, d, J = 2.1 Hz,
H1a), 3.25 (1H, t, J = 2.3 Hz, H2¢), 2.39 (3H, s, CH3) ppm;
dC (101 MHz, DMSO-d6): 178.1, 159.4, 136.8, 136.2, 134.6, 132.6,
132.1, 129.1, 124.3, 120.0, 115.0, 78.8, 74.6, 31.3, 20.1 ppm;
vmax(neat, cm
–1): 3279 (NH), 3183 (NH), 1627 (C=O), 1522 (C=N),
1206 (C=S), 836 (C-S); HRMS (ESI) m/z calcd for C15H14N4OS:
314.0837, found 315.0927 [M+H] + ; Anal . calcd for
C15H14N4OS·0.75CH3OH·1H2O: C, 55.57, H; 5.63, N; 16.46,
S; 9.42 %. Found; C; 55.32, H; 5.58, N; 16.8, S; 9.98 %.
(E)-2-((1-(2-((7-Chloroquinolin-4-yl)amino)ethyl)-2-oxo-1,2-dihydro
quinolin-3-yl)methylene)hydrazinecarbothioamide (9n): 68 yield;
yellow solid; mp 235–237 °C; dH(400 MHz; DMSO-d6): 12.6 (1H, s,
NH), 8.80 (1H, s, H9), 8.44 (1H, d, J = 5.3 Hz, H2’), 8.35 (1H, s, H4),
8.33 (1H, br s, NHH) 8.11 (1H, brs, NHH), 8.06 (1H, d, J = 9.1 Hz,
H5’), 7.97 (1H, d, J = 1.9 Hz, H8’), 7.71 (1H, d, J = 7.6 Hz, H5), 7.60
(1H, t, J = 8.6 Hz, H7), 7.57 –7.47 (2H, m, H5 and NH), 7.45 (1H, dd,
J =1.9 and 9.1 Hz, H6’), 7.28 (1H, t, J = 7.4 Hz, H6), 6.72 (1H, d, J =
5.4 Hz, H3’), 4.56 (2H, t, J = 6.6 Hz, CH2), 4.09 (2H, q, J = 6.0, 7.5
and 8.8 Hz, CH2) ppm; dC(101 MHz, DMSO-d6): 178.7, 161.2,
152.5, 150.5, 149.5, 139.7, 137.4, 133.4, 131.9, 130.2, 128.0, 124.9,
124.8, 124.7, 124.2, 123.2, 120.7, 114.9, 99.1, 49.1, 41.1 ppm;
vmax(neat, cm
–1): 3234 (NH), 3150 (NH), 1633 (C=O), 1515 (C=N),
1204 (C=S), 844 (C-S), 716 (C-Cl); HRMS (ESI) m/z calcd for
C22H19ClN6OS: 450.1030, found 451.1099 [M+H]
+; Anal. calcd.
for C22H19ClN6OS: C, 58.60; H, 4.25; N, 18.64; S, 7.11 %, Found:
C, 59.21; H, 4.22; N, 18.55; S, 6.99 %.
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(E)-2-((1-(3-((7-Chloroquinolin-4-yl)amino)propyl)-2-oxo-1,2-dihydro-
quinolin-3-yl)methylene)hydrazinecarbothioamide (9o): 48 % yield;
amorphous yellow solid; mp 240–242 °C; dH(400 MHz;
DMSO-d6): 11.6 (1H, s, N(11)H), 8.78 (1H, s, H9), 8.38 (1H, d, J =
5.3 Hz, H2’), 8.34 (1H, s, H4), 8.32 (1H, br s, NHH), 8.25 (1H, d, J =
9.0 Hz, H5’), 8.10 (1H, br s, NHH), 7.79 (1H, d, J = 1.8 Hz, H8’), 7.72
(1H, d, J = 1.0 and 7.7 Hz, H8), 7.63 (1H, d, J = 0.7 and 8.6 Hz, H5),
7.55 (1H, ddd, J = 1.0, 7.2 and 9.0 Hz, H6), 7.46 (1H, dd, J = 1.8 and
9.0 Hz, H6’), 7.39 1H, s, NH), 7.30 (1H, ddd, J = 0.7, 7.2 and 8.6Hz,
H7), 6.50 (1H, d, J = 5.4 Hz, H3’), 4.47–4.39 (2H, m, H1’), 3.45–3.41
(2H, m, H3’), 2.10–2.01 (2H, m, H2’) ppm; dC (101 MHz, DMSO-d6):
178.6, 165.3, 160.6, 152.4, 150.5, 139.3, 137.6, 133.9, 130.2, 128.0,
124.9, 124.9, 124.7, 124.6, 124.4, 124.4, 123.1, 120.7, 118.0, 115.1,
99.2, 40.8, 39.3, 26.7 ppm; vmax(neat, cm
–1): 3325 (NH), 3234 (NH),
1641 (C=O), 1505 (C=N), 1194 (C=S), 854 (C-S), 712 (C-Cl);
HRMS (ESI) m/z calcd for C23H21ClN6OS: 464.1186, found
465.1268 [M+H]+; Anal. calcd for C23H21ClN6OS: C, 59.41;
H, 4.55; N, 18.07; S, 6.90 %. Found: C, 59.82; H, 4.44; N, 17.93;
S, 6.63 %.
(E)-2-((1-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)-2-oxo-1,2-dihy-
droquinolin-3-yl)methylene)hydrazinecarbothioamide (9p): 45 %
yield; yellow solid; mp 240–242 °C; dH(400 MHz; DMSO-d6): 11.7
(1H, s, N(11)H), 8.81 (1H, s, H9), 8.35 (1H, s, H4), 8.32 (1H, br s,
NHH), 8.11 (1H, br s, NHH), 8.08 (1H, s, H5’), 7.73–7.70 (2H, m, H2’
and H6’), 7.38 (1H, ddd, J = 1.2 and 7.3, 9.0 Hz, H6), 7.37–7.24 (6H,
m, H5, H7, H8, H5’, H4’ and H3’), 5.55 (2H, s, H4a), 5.51 (2H, s,
H1a) ppm; dC(101 MHz, DMSO-d6): 178.1, 160.2, 142.8, 138.9,
136.9, 135.4, 134.7, 131.3, 129.6, 128.7, 128.1, 127.9, 124.5, 123.7,
122.7, 120.1, 115.1, 52.7, 37.7 ppm; vmax(neat, cm
–1): 3215 (NH),
3156 (NH), 1634 (C=O), 1524 (C=N), 1567 (N=N), 1203 (C=S),
843 (C-S); HRMS (ESI) m/z calcd for C21H19N7OS: 417.1372, found
418.1455 [M+H]+; Anal. calcd for C21H19N7OS·0.125H2O:
C, 60.09; H, 4.62; N, 23.36; S, 7.64 %. Found: C, 60.04; H, 4.52;
N, 22.99; S, 7.34 %.
(E)-2-((1-((1-(4-Nitrobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2-oxo-1,
2-dihydroquinolin-3-yl)methylene)hydrazinecarbothioamide (9q):
55 % yield; yellow solid; mp 258–260 °C; dH(400 MHz; DMSO-d6):
11.7 (1H, s, N(11)H), 8.80 (1H, s, H9), 8.35 (1H, s, H4), 8.33 (1H, br s,
NHH), 8.22–8.18 (2H, m, H3’’ and H5’’), 8.17 (1H, s, H5’), 8.11 (1H, s,
NHH), 7.74–7.70 (2H, m, H5 and H8), 7.62 (1H, ddd, J = 1.3, 7.2
and 8.9 Hz, H6), 7.52–7.47 (2H, m, H2’’ and H6’’), 7.31 (1H, ddd, J =
0.5, 7.2 and 8.4 Hz, H7), 5.71 (2H, s, H4a), 5.58 (2H, s, H1a) ppm;
dC(101 MHz, DMSO-d6): 178.1, 160.3, 147.3, 143.4, 143.1, 138.9,
136.9, 134.8, 131.5, 129.2, 124.6, 124.3, 123.9, 122.9, 120.2, 51.9 ppm;
vmax(neat, cm
–1): 3361 (NH), 3255 (NH), 1635 (C=O), 1514 (C=N),
1564 (N=N), 1202 (C=S), 847 (C-S); HRMS (ESI) m/z calcd for
C21H18N8O3S: 462.1223, found 463.1306 [M+H]
+; Anal. calcd for
C21H18N8O3S·0.5H2O: C, 53.50; H, 4.06; N, 23.77; S, 6.80 %. Found:
C, 53.33; H, 3.77; N, 23.95; S, 6.58 %.
(E)-2-((1-((1-(7-Chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-
2-oxo-1,2-dihydroquinolin-3-yl)methylene)hydrazinecarbothioamide
(9r): 46 % yield; amorphous yellow solid; mp 251–253 °C;
dH(300 MHz; DMSO-d6): 11.7 (1H, s, N(11)H), 9.10 ( 1H, d, J = 4.6
Hz, H2’’), 8.84 (1H, s, H9), 8.77 (1H, s, H5’), 8.38 (1H, s, H4), 8.33 (1H,
br s, NHH), 8.26 (1H, d, J = 1.8 Hz, H8’), 8.13 (1H, br s, NHH), 7.97
(1H, d, J = 8.9 Hz, H5’), 7.85–7.72 (4H, m, H5, H8, H3’ and H6’), 7.67
(1H, ddd, J = 1.3, 7.0 and 8.9 Hz, H6), 7.34 (1H, ddd, J = 0.6, 7.0, 8.6
Hz, H7), 5.76 (2H, s, H4a) ppm; dC(75 MHz, DMSO-d6): 178.1,
160.2, 152.9, 149.3, 143.5, 140.2, 139.0, 136.9, 136.3, 134.8, 131.4,
129.7, 128.9, 128.1, 125.9, 125.4, 124.6, 122.8, 120.2, 117.0, 115.2,
37.5 ppm; vmax(neat, cm
–1): 3358 (NH), 3233 (NH), 1638 (C=O),
1517 (C=N), 1568 (N=N), 1516 (C=N), 1205 (C=S), 851 (C-S);
HRMS (ESI) m/z calcd for C23H17ClN8OS: 488.0935, found
489.1011 [M+H]+. Anal. calcd for C23H17ClN8OS·0.25H2O:
C, 55.98; H, 3.57; N, 22.71; S, 6.50 %. Found: C, 55.81; H, 3.46;
N, 23.01; S, 6.62 %.
4.3. Biological Testing and Growth Inhibition Assays
4.3.1. In Vitro Antitrypanosomal and Cytotoxicity Assays
The HeLa cells (Cellonex) were cultured using method de-
scribed by Oderinlo et al. and Adeyemi et al.30,31 Trypanosoma
brucei brucei 427 trypomastigotes were cultured in Iscove’s
Modified Dulbecco’s Medium (IMDM; Lonza) supplemented
with 10 % fetal calf serum, HMI-9 supplement,32 hypoxanthine
and penicillin/streptomycin at 37 °C in a 5 % CO2 incubator.
Serial dilutions of test compounds were incubated with the para-
sites in 96-well plates for 24 h and residual parasite viability in
the wells determined by adding 20 µL of 0.54 mM resazurin
in phosphate buffered saline (PBS) and incubating for an addi-
tional 24 h. Reduction of resazurin to resorufin by viable para-
sites was assessed by fluorescence readings (excitation 560 nm,
emission 590 nm) in a Spectramax M3 plate reader. Fluorescence
readings were converted to % parasite viability relative to the
average readings obtained from untreated control wells. IC50
values were determined by plotting % viability vs. log[com-
pound] and performing non-linear regression using GraphPad
Prism (v. 5.02) software.30,31
4.3.2. In Vitro Antiplasmodial Assay
Activity was determined against the 3D7 chloroquine-
sensitive strain of P. falciparum. Parasites were maintained in
continuous culture using the method of Trager and Jensen33 with
modifications. Growth medium consisted of RPMI 1640 contain-
ing 25 mM HEPES, and further supplemented with 0.5 % (w/v)
Albumax II, 22 mM glucose, 0.65 mM hypoxanthine, 0.05 mg mL–1
gentamicin and 2–4 % (v/v) human erythrocytes. Parasites were
cultured at 37 °C under an atmosphere of 5 % CO2, 5 % O2, 90 %
N2.
30,31 Compounds were prepared as 20 mM stock solutions in
dimethyl sulfoxide, sonicated for 10 minutes to enhance solubil-
ity and stored at –20 °C until use. To assess antimalarial activity,
compounds were diluted to a final concentration of 20 µM in
culture medium, added to parasite cultures (2 % parasitaemia,
1 % haematocrit) in 96 well plates and incubated for 48 h at 37 °C
under an atmosphere of 5 % CO2, 5 % O2, 90 % N2. Parasite viabil-
ity was assessed using the parasite lactate dehydrogenase assay
described by Makler et al.34 Wells containing uninfected erythro-
cytes were used as negative controls (0 % parasite viability) and
untreated parasite-infected wells as positive controls (100 %
parasite viability). To determine IC50-values, parasite cultures
were incubated with 3-fold serial dilutions of test compounds
and non-linear regression analysis carried out on dose-response
plots of % parasite viability vs. log[compound] using GraphPad
Prism (v. 5.02) software.
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